Tag: HUYABIO

HUYABIO INTL. PRESENTS POSITIVE CLINICAL RESULTS FROM HBI-3000 PHASE 2A CLINICAL TRIAL OF NOVEL MULTI-ION CHANNEL BLOCKER FOR ACUTE ATRIAL FIBRILLATION

Rhythm by Comments are Disabled

Authors: Denis Roy1, Suzanne Romano2, Jay W. Mason3, Monica Wynn2, Charles Pollack4, Gary Elliot5, Mireille Gillings2, Jerome B. Riebman2 SAN DIEGO, April 24, 2025 /PRNewswire/ — HUYABIO International today announced the presentation of new patient data for HBI-3000, a novel bioinspired…

Continue Reading →

HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment

Rhythm by Comments are Disabled

HBI-3000 Aims to Fill Critical Gaps in Atrial Fibrillation Care; Key Data to be Presented at the American Heart Association Annual Meeting SAN DIEGO, Nov. 14, 2024 /PRNewswire/ — HUYABIO International today announced the presentation of new patient data for HBI-3000, an antiarrhythmic…

Continue Reading →

HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2

Rhythm by 0 comments

Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with thestrong CYP2D6 inhibitor, paroxetine SAN DIEGO, May 17, 2022 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion […]

Continue Reading →